moatshark My

All holdings

Quest Diagnostics

DGX

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
3
In their latest 13F (Q3 2026)
See who
Value held
$332m
Combined value at quarter end
Last quarter
1 bought
1 sold or trimmed
Price at Q2 ’26 end
$211.95
+8.1% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+13.4%Q3 ’24
-2.8%Q4 ’24
+12.2%Q1 ’25
+6.2%Q2 ’25
+6.1%Q3 ’25
-8.9%Q4 ’25
+12.9%Q1 ’26
+8.1%Q2 ’26
Q3 ’24: +13.4%; Q4 ’24: -2.8%; Q1 ’25: +12.2%; Q2 ’25: +6.2%; Q3 ’25: +6.1%; Q4 ’25: -8.9%; Q1 ’26: +12.9%; Q2 ’26: +8.1%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

3Q4 ’23
3Q1 ’24
3Q2 ’24
3Q3 ’24
3Q4 ’24
3Q1 ’25
3Q2 ’25
3Q3 ’25
3Q4 ’25
3Q1 ’26
3Q2 ’26
0Q3 ’26
Q4 ’23: 3; Q1 ’24: 3; Q2 ’24: 3; Q3 ’24: 3; Q4 ’24: 3; Q1 ’25: 3; Q2 ’25: 3; Q3 ’25: 3; Q4 ’25: 3; Q1 ’26: 3; Q2 ’26: 3; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Quest Diagnostics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Quest Diagnostics
Davis Selected Advisers1.4%$330m$330mTrimmed -3.8%50 qtrs
Horizon Kinetics0.0%$615k$615kUnchanged30 qtrs
First Eagle Investment Management0.0%$1.6m$1.6mAdded +154%18 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Quest Diagnostics
Bought or soldFiling
1 Sep 2026Davis J. E.CEO and President▼ Sold10,000$242.72$2.4mForm 4
28 Aug 2026Prevoznik Michael ESVP & General Counsel▼ Sold16,010$242.88$3.9mForm 4
28 Aug 2026Prevoznik Michael ESVP & General Counsel▼ Sold6,237$243.63$1.5mForm 4
28 Aug 2026Prevoznik Michael ESVP & General Counsel▼ Sold430$244.51$105kForm 4
28 Jul 2026Delaney Mark ESVP & Chief Commercial Officer▼ Sold1,600$235.18$376kForm 4

About the company

Sector
Health care · Services-Medical Laboratories
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
110m at 15 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$7.1bn2013
$7.5bn2015
$7.4bn2017
$7.7bn2019
$11bn2021
$9.3bn2023
$11bn2025
2013: $7.1bn; 2014: $7.4bn; 2015: $7.5bn; 2016: $7.2bn; 2017: $7.4bn; 2018: $7.5bn; 2019: $7.7bn; 2020: $9.4bn; 2021: $11bn; 2022: $9.9bn; 2023: $9.3bn; 2024: $9.9bn; 2025: $11bn
Quest Diagnostics revenue and net income by year
YearRevenueNet income
2025$11bn$992m
2024$9.9bn$871m
2023$9.3bn$854m
2022$9.9bn$946m
2021$11bn$2.0bn
2020$9.4bn$1.4bn
2019$7.7bn$858m
2018$7.5bn$736m
2017$7.4bn$772m
2016$7.2bn$645m
2015$7.5bn$709m
2014$7.4bn$556m
2013$7.1bn$849m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.